首页 | 本学科首页   官方微博 | 高级检索  
     

伊潘立酮片在中国健康受试者空腹和餐后条件下的生物等效性研究
引用本文:王月琴,李泽运,刘帅兵,孟志宾,赫晓林,彭悦颖,张晓坚,田鑫. 伊潘立酮片在中国健康受试者空腹和餐后条件下的生物等效性研究[J]. 中国药学杂志, 2022, 57(5): 379-384. DOI: 10.11669/cpj.2022.05.008
作者姓名:王月琴  李泽运  刘帅兵  孟志宾  赫晓林  彭悦颖  张晓坚  田鑫
作者单位:1.郑州大学第一附属医院药学部, 郑州 450052;
2.石药集团中奇制药有限公司, 石家庄 050000
基金项目:国家科技重大专项重大新药创制项目资助(2020ZX09201-009)
摘    要:目的 研究伊潘立酮片在中国健康受试者空腹和高脂条件下体内的药动学特征并评价生物等效性.方法 采用开放、随机、两周期、两序列自身交叉试验设计,健康受试者分别空腹和餐后口服1 mg伊潘立酮片受试制剂与参比制剂,采集不同时间点的血样.利用液相色谱-质谱联用法检测血浆样品中伊潘立酮及其代谢物羟基伊潘立酮(P88)的浓度,用Ph...

关 键 词:伊潘立酮  羟基伊潘立酮  生物等效性  药动学
收稿时间:2020-12-02

Bioequivalence Study of Iloperidone Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects
WANG Yue-qin,LI Ze-yun,LIU Shuai-bing,MENG Zhi-bin,HE Xiao-lin,PENG Yue-ying,ZHANG Xiao-jian,TIAN Xin. Bioequivalence Study of Iloperidone Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects[J]. Chinese Pharmaceutical Journal, 2022, 57(5): 379-384. DOI: 10.11669/cpj.2022.05.008
Authors:WANG Yue-qin  LI Ze-yun  LIU Shuai-bing  MENG Zhi-bin  HE Xiao-lin  PENG Yue-ying  ZHANG Xiao-jian  TIAN Xin
Affiliation:1. Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
2. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang 050000, China
Abstract:OBJECTIVE To study the pharmacokinetics and bioequivalence of iloperidone tablets in Chinese healthy subjects under fasting and fed conditions. METHODS An open, randomized, single-dose, double-period, two-sequence and self-crossover design was adopted. Thirty-six Chinese healthy subjects were randomly divided into two groups under fasting and fed conditions. Blood samples were collected at different time points from the subjects after taking a single dose of 1 mg iloperidone test tablets (T) or reference tablets (R) orally. The concentrations of iloperidone and its metabolite P88 in plasma samples were determined by liquid chromatography-mass spectrometry (LC-MS/MS). The main pharmacokinetic parameters of the two preparations were calculated by PhoenixTM WinNonlin 7.0 software, and the bioequivalence of the two preparations was evaluated. RESULTS Under fasting conditions, the 90% confidence intervals of ρmax, AUC0-t and AUC0-∞ of plasma iloperidone were 89.88%-106.6%, 99.81%-109.40% and 100.06%-110.20%, respectively; the 90% confidence intervals of ρmax, AUC0-t and AUC0-∞ of its metabolite P88 were 90.05%-102.45%, 100.79%-108.17% and 101.58%-110.97%. Under fed conditions, the 90% confidence intervals of ρmax, AUC0-t and AUC0-∞ of plasma iloperidone were 102.06%-118.14%, 103.94%-111.83% and 104.02%-113.02%, respectively; the 90% confidence intervals of ρmax, AUC0-t and AUC0-∞ of its metabolite P88 were100.73%-111.20%, 104.88%-112.29% and 103.29%-111.33%. The 90% confidence intervals of the T:R ratios of ρmax, AUC0-t and AUC0-∞ were all within the equivalent interval of 80.00%-125.00% under fasting and fed conditions. CONCLUSION The test preparation and reference preparation of iloperidone tablets were bioequivalent in Chinese healthy subjects under fasting and fed conditions.
Keywords:iloperidone  hydroxy iloperidone  bioequivalence  pharmacokinetics   
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号